# A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

> **NCT03096990** · — · COMPLETED · sponsor: **Amgen** · enrollment: 106 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** apremilast

## Key facts

- **NCT ID:** NCT03096990
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-21
- **Primary completion:** 2018-12-27
- **Final completion:** 2018-12-27
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096990, "A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03096990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*